Colorectal Cancer

It is unlikely that guidelines recommend screening patients younger than 45 years for colorectal cancer, according to Yoanna S. Pumpalova, MD.

The NHS-Galleri study findings showed that multicancer screening with the Galleri test did not reduce the number of cancers found at stage III or IV.

Marc Lehrer Greenwald, MD, spoke with CancerNetwork® about how North Shore University Hospital treats young patients with colorectal cancer.

Marc Lehrer Greenwald, MD, discussed a recent patient case he had with a 22-year-old woman who was diagnosed with colorectal cancer.

The rising incidence of colorectal cancer among younger populations may be due to environmental factors, according to Marc Greenwald, MD.

According to Marwan G. Fakih, MD, neutropenia may be a biomarker of benefit for patients with metastatic colorectal cancer receiving trifluridine/tipiracil and bevacizumab.

Patients with metastatic colorectal cancer who desire better disease control are best served with trifluridine/tipiracil plus bevacizumab, according to Marwan G. Fakih, MD.

Marwan G. Fakih, MD, discussed many of the factors he considers when deciding on a treatment for a patient with metastatic colorectal cancer.

Development of the oral DHX9 inhibitor, ATX-559, has been halted following adverse events in a phase 1/2 trial of patients with metastatic solid tumors.

Results from the BREAKWATER trial led to the traditional approval of encorafenib plus cetuximab and fluorouracil-based chemotherapy in BRAF-mutated CRC.

Phase 2 CRDF-004 findings show that adding onvansertib to FOLFIRI and bevacizumab improves PFS in first-line RAS-mutated metastatic colorectal cancer.

Encorafenib, cetuximab, and FOLFIRI improved PFS vs in treatment-naive BRAF V600E-mutant metastatic colorectal cancer in the BREAKWATER trial.

Prior phase 1 data support the fast track designation for pelareorep as a treatment for those with KRAS-mutated microsatellite stable colorectal cancer.

Treatment with zanzalintinib plus atezolizumab led to improvements in OS and PFS vs regorafenib alone in patients with metastatic colorectal cancer.

According to investigators of the phase 3 SCOT trial, most patients with colon and rectal cancer should be receiving only 3 months of adjuvant treatment.

People who consumed 14 or more drinks per week experienced a higher risk of colorectal cancer compared with those who consumed one or fewer drinks.

Data from the phase 3 BREAKWATER trial demonstrated that encorafenib plus cetuximab and chemotherapy yields clinical benefit for this patient population.

The Taiwan FDA has approved nivolumab/ipilimumab for patients with MSI-H/dMMR metastatic colorectal cancer based on data from CheckMate 8HW.

Next steps in surgery for gastroesophageal cancer include offerings for patients with advanced disease, such as those with oligometastases.

Data from the GALAXY study in Japan may inform future use of total neoadjuvant therapy among patients with rectal cancer in the US.

Bodies like the NCCN must keep up with data related to ctDNA so that it can be incorporated in a measured manner, said Nicholas Hornstein, MD, PhD.

No serious adverse effects were observed with CBM588 in patients at risk of colorectal adenoma recurrence.

Larger-scale and longer-term studies could elucidate the mechanisms underlying quality of life benefits associated with resistance exercise in this group.

The addition of pelareorep to standard-of-care therapy in patients with KRAS-mutated microsatellite-stable CRC exhibited an ORR of 33%.

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.